Own Pain Relief Solution Store In Your City | Franchise Sales & Distribution Call us on 8691006638
Preventive anticoagulation is a key component in modern clinical care, particularly in reducing the risk of thromboembolic complications in surgical and immobilized patients. Low molecular weight heparins (LMWH) are widely preferred due to their predictable pharmacokinetics, safety profile, and ease of administration in hospital settings.
ENOXABARA® (Enoxaparin Injection) is developed by RAWIA INTERNATIONAL HEALTHCARE (RIHCA) in collaboration with leading pharmaceutical manufacturing partners and marketed through RAWIACARE. The 40 mg strength is specifically designed for thromboprophylaxis, supporting healthcare professionals in preventing clot formation and improving patient safety across regional and international healthcare markets — To Share • To Care • To Inspire.
ENOXABARA® 40 mg (Enoxaparin Sodium Injection) is a low molecular weight heparin (LMWH) primarily indicated for the prevention of thromboembolic disorders. It works by inhibiting factor Xa activity, reducing clot formation and supporting stable blood flow.
This strength is commonly used in surgical patients, bedridden individuals, and those at risk of venous thromboembolism (VTE), particularly in hospital and post-operative care settings.
| Specifications Table | |
| Parameter | Details |
| Brand Name | ENOXABARA® |
| Generic Name | Enoxaparin Sodium |
| Arabic BRAName | إينوكسابارا |
| Category | Anticoagulants |
| Therapeutic Area | Low Molecular Weight Heparin |
| Dosage Form | Injection |
| Strength | 40 mg |
| Volume | 0.4 ml |
| Route / Type | Subcutaneous (Anti-Xa) |
| Developed By | RIHCA |
| Platform Name | RAWIACARE / RAWIACARE GLOBAL |
| Prevention of Deep Vein Thrombosis (DVT) |
| Post-surgical thromboprophylaxis |
| Prevention of Venous Thromboembolism (VTE) |
| Anticoagulant support in immobilized patients |
| Hospital-based preventive protocols |
| It is used for the prevention of thromboembolic conditions, especially in surgical and immobilized patients. |
| It inhibits factor Xa activity, reducing clot formation and maintaining blood flow. |
| Patients requiring preventive anticoagulation under medical supervision. |
Subcutaneous injection.
| 40 mg, 60 mg, 80 mg |
